Full-Time

Senior Scientist Drug Discovery Biochemistry & Biophysics

Drug Discovery Biochemistry & Biophysics

Updated on 9/4/2026

Integrated Biosciences

Integrated Biosciences

11-50 employees

AI-driven synthetic biology therapeutics discovery

No salary listed

H1B Sponsorship Available

San Carlos, CA, USA

In Person

On-site in Redwood City, California. Visa sponsorship available where applicable.

PhD

Category
Biology & Biotech (1)
Required Skills
Biophysics
Medicinal Chemistry
Chemical Biology
Cell Biology
Biochemistry
Pharmacology
Biochemical Assays

Get referred to Integrated Biosciences

See people who can refer or advise you

Requirements
  • PhD in biochemistry, biophysics, chemical biology, structural biology, pharmacology, cell biology, or a closely related field
  • 3–5 years of industry experience in small molecule drug discovery, developing biochemical, biophysical, and/or cellular assays
  • Hands-on experience in recombinant protein expression, purification, and analytical characterization, independently generating high-quality reagents for quantitative assays
  • A strong grasp of assay development principles, including robustness, reproducibility, dynamic range, signal-to-background, Z' factor, and coefficient of variation
Responsibilities
  • Design, express, purify, and characterize recombinant proteins to support biochemical, biophysical, target engagement, and structural studies
  • Develop construct, tag, truncation, mutation, and purification strategies, and apply analytical methods (SEC, SDS-PAGE, activity, LC-MS, DLS, thermal shift, etc.) to assess protein purity, identity, oligomeric state, stability, and assay suitability
  • Develop, validate, and run biochemical and biophysical assays (fluorescence resonance energy transfer FR, time-resolved FRET, AlphaScreen/AlphaLISA, differential scanning fluorimetry DSF, enzymatic, surface plasmon resonance SPR, bio-layer interferometry BLI) to support hit validation, structure-activity relationships SAR, selectivity, mechanism of action, and lead optimization
  • Generate quantitative data on affinity, potency, kinetics, residence time, reversibility, competition, allostery, selectivity, and design orthogonal assays
  • Partner with medicinal chemistry to interpret SAR, prioritize compounds, and shape assay strategy
  • Build focused cell-based assays that connect biochemical/biophysical target engagement to cellular pharmacology, covering target engagement, pathway modulation, biomarker response, potency, selectivity and counterscreens
  • Develop fit-for-purpose readouts (e.g. high-content cell imaging, qPCR, reporter, viability) for SAR and mechanism
Desired Qualifications
  • Experience with structural biology methods such as NMR, X-ray crystallography, or cryo-electron microscopy
  • Familiarity with aging biology, senescence, mitochondrial function, proteostasis, inflammatory signaling, metabolic pathways, or other age-related disease biology
  • Experience leveraging artificial intelligence and coding agents in the context of drug discovery, computational chemistry, and leveraging large-scale biological datasets to augment drug discovery
Integrated Biosciences

Integrated Biosciences

View

Integrated Biosciences develops therapies for age-related diseases using a platform that blends synthetic biology, AI-driven small-molecule drug discovery, optogenetics, chemistry, and computation. The platform helps scientists understand complex cellular stress biology and identify compounds that modulate stress responses linked to neurodegeneration, cancer, and diabetes. Drugs are discovered and developed through research and development efforts, with the goal of bringing new therapeutics to patients. Unlike traditional pharma approaches that rely on a single method, Integrated Biosciences combines biology engineering, machine learning, and precision chemistry to accelerate the discovery and optimization of drug candidates.

Company Size

11-50

Company Stage

Late Stage VC

Total Funding

$85.6M

Headquarters

San Carlos, California

Founded

2022

Get referred to Integrated Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 fundraising reports $68.4 million, extending runway after the 2024 $17.2 million seed.
  • Tony Wu joined the Scientific Advisory Board in February 2026, adding frontier-model expertise.
  • The company touts sixfold senolytic hit-rate gains and multi-year LVMH research support.

What critics are saying

  • Integrated Biosciences still has no disclosed clinical candidate or human trial by September 2026.
  • The platform depends on unproven AI biology translation; failures before 2027 erase valuation.
  • LVMH and seed financing do not guarantee drug approvals, and commercialization remains years away.

What makes Integrated Biosciences unique

  • Jim Collins, David MacMillan, and Daniel Anderson anchor a rare aging-drug discovery bench.
  • Optogenetics plus AI enables precise transcriptome control, unlike standard virtual screening.
  • LVMH Recherche partnership broadens the platform into beauty, not only therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

6%
Medium
Aug 13th, 2026
$771.8M Across 5 Fresh SEC Form D Raises This Week

Five new SEC Form D filings hit EDGAR this week, together raising $771.8M. Here’s the roundup, scored for B2B sales relevance by Funding…

Investors Hangout
May 19th, 2026
Integrated Biosciences raises $17M to develop age-related disease treatments with AI

Integrated Biosciences has secured $17.2 million in seed financing led by Sutter Hill Ventures to develop therapeutics targeting age-related diseases. The company combines synthetic biology and artificial intelligence to enhance drug discovery, employing techniques including optogenetics for precise cellular data control. The funding will accelerate development of the company's drug pipeline, enhance its platform and support commercialisation efforts. Integrated Biosciences benefits from advisors with expertise in medical engineering, systems biology and drug development, providing insight into translational medicine. The company's approach uses machine learning alongside synthetic biology to innovate the drug discovery process for age-related conditions.

Business Wire
Feb 19th, 2026
xAI co-founder Tony Wu joins Integrated Biosciences' scientific advisory board

Integrated Biosciences, a biotechnology company using optogenetics, chemistry and AI to discover therapeutics for age-related diseases, has appointed Tony Wu, co-founder of xAI, to its Scientific Advisory Board. Wu played a key role in building Grok, xAI's reasoning and agentic AI model, and scaling the Colossus supercomputer cluster. His expertise in large-scale model training and AI applications to scientific discovery will support Integrated Biosciences' platform, which has demonstrated sixfold improvements in hit rates for senolytic compounds and breakthroughs in virtual staining and biological age inference from microscopy. The appointment strengthens the company's advisory board, which includes experts in ageing biology, drug discovery and a Nobel Prize winner in chemistry. Integrated Biosciences is based in Redwood City, California.

Associated Press
Jan 27th, 2026
Integrated Biosciences names Daniel Anderson chief scientific officer to advance age-related disease pipeline

Integrated Biosciences has appointed Daniel J. Anderson as chief scientific officer. Anderson joins from Eikon Therapeutics, where he served as CSO and managed a team of 130 scientists leading discovery and translational research efforts. In his new role, Anderson will oversee scientific strategy and pipeline development at Integrated Biosciences, which combines synthetic biology, chemistry and AI to discover small-molecule therapeutics for age-related diseases. He previously held positions at Recursion Pharmaceuticals, Cleave Biosciences and Genentech, advancing 10 programmes into clinical trials. Max Wilson, co-founder of Integrated Biosciences, has moved to chief technology officer, where he will focus on advancing the company's technology platform, including AI-enabled discovery systems and high-throughput biological screening.

Business Wire
Oct 8th, 2024
Integrated Biosciences Raises $17 Million to Accelerate Development of Drugs Targeting Age-Related Diseases

Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics f